간편하게 보는 뉴스는 유니콘뉴스
In-Depth Report on Global Oesophageal Cancer Clinical Trials Now Available

· 등록일 Aug. 02, 2024 09:40

· 업데이트일 2024-08-03 00:01:26

SAN FRANCISCO--(Business Wire / Korea Newswire)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, has released its latest industry report, Oesophageal Cancer — Global Clinical Trial Landscape.

This detailed analysis focuses on the extensive research and innovative treatments being developed to combat oesophageal cancer (OC), the seventh leading cause of cancer mortality worldwide, and the 11th most diagnosed cancer globally, with Asia accounting for nearly 70% of cases. Other areas of the report detail the research pipeline for OC, highlighting significant advancements in treatments aimed at improving patient outcomes as well as providing a robust analysis of the funding landscape from both public and private sources, which is currently led by entities based in China and the USA with approximately $5B USD in investment across those two nations.

The Novotech research analyst team provides these expert reports monthly, highlighting key metrics on the current status of specific diseases and outlining future trends that may impact the development of treatments. This is provided completely free of charge.

Key takeaways from the report:

Global Clinical Trial Activity:

· Since 2019, over 1,530 clinical trials for OC have been initiated globally, with the Asia-Pacific region (49%), North America (28%), and Europe (18%) leading the research efforts.
· Countries such as China, South Korea, Japan, and the USA are at the forefront of trial activities.

Rising Incidence:

· OC is the 11th most diagnosed cancer globally, with approximately 511,000 new cases and 445,400 deaths in 2022.
· By 2050, the annual incidence is projected to rise to 923,000 new cases, an 80.5% increase.

Innovative Treatment Approaches:

· The treatment landscape is shifting towards personalized medicine, with systemic therapies based on disease stage and molecular markers being recommended by the 2024 NCCN and 2022 ESMO Guidelines.
· The development pipeline is robust, with over 90 drugs in progress, including numerous Phase III trials focusing on diverse mechanisms of action.

Funding and Investment:

· Significant investment has been channeled into OC research, with China leading with $2.9 billion USD and the USA following with $2.1 billion USD.
· Other notable contributors include Switzerland, Singapore, Canada, and Japan.

Market Leaders:

· The report identifies key players in the OC treatment market, including Advanz Pharma Corp. Ltd, BeiGene Ltd., InnoKeys Pte. Ltd., and Simcere Pharmaceutical Group Ltd.

Strategic Insights:

· The report includes a SWOT analysis, demonstrating the effectiveness of current treatments in managing symptoms and improving quality of life, while also identifying areas where emerging techniques may offer improvements.

Download the report here

About Novotech

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit here

View source version on businesswire.com: https://www.businesswire.com/news/home/20240729339816/en/

Website: https://novotech-cro.com/kr/about?utm_ca... Contact Novotech
Toyna Chin
USA : +1 415 364 8135
[email protected]
This news is a press release provided by Novotech. Korea Newswire follows these editorial guidelines. Novotech News ReleasesSubscribeRSS More News Health Biotechnology Clinical Trials Survey & Analysis Overseas Novotech All News Releases 
인기 기사12.23 23시 기준
수원--(뉴스와이어)--삼성전자가 국내 누적 판매 1000만 대를 돌파한 무풍에어컨 생산라인의 풀가동에 들어가며 여름을 맞이하는 동시에 국내 에어컨 시장 공략 강화에 나섰다. 삼성전자가 국내 누적 1000만대 판매를...
수원--(뉴스와이어)--삼성전자가 라이프스타일 TV ‘더 프레임(The Frame)’을 통해 20세기 아티스트 ‘키스 해링(Keith Haring)’의 작품을 선보인다. 삼성전자가 라이프스타일 TV ‘더 프레임’을 통해 20세기 아티스트 ‘키스 해링’의 작품을 선보인다. 더 프레임을 통해 만날 수 있는 ‘회고(Retrospect)’ 작품 삼성전자는...
멜버른, 호주--(Business Wire / 뉴스와이어)--옵티스캔 이미징(Optiscan Imaging Limited)(호주증권거래소: OIL)(이하 ‘옵티스캔’ 또는 ‘회사’)이 메이요 클리닉과 노하우 협력 계약을 체결하고 로봇 수술에 사용할 디지털 공초점 레이저 내시경 영상 시스템을 개발한다고 발표했다. 이번 협력을 통해 디지털 내시경...
서울--(뉴스와이어)--세계적인 타블렛 전문 기업 와콤(Wacom)의 한국법인 한국와콤(대표 김주형, www.wacom.com)이 전국 대학교 내 웹툰학과 대상으로 ‘와콤 웹툰 장학금 프로그램’을 진행, 세 번째 학교로 수성대학교 웹툰스토리과와 메타버스크리에이터과에서 장학기자재 수여식을 개최했다. ...
토론토--(Business Wire / 뉴스와이어)--전 세계 기술 인프라를 위한 고속 연결성의 글로벌 리더인 알파웨이브 세미(Alphawave Semi)(런던증권거래소: AWE)와 프로토콜 테스트 및 측정 솔루션의 세계적인 리더인 텔레다인르크로이(Teledyne LeCroy)는 오늘 캘리포니아주 산타클라라에서 개최된 디자인콘(DesignCon)에서 PCI ExpressⓇ 7.0 신호...
서울--(뉴스와이어)--국내 로봇 및 소프트웨어 개발기업 ‘고스트로보틱스 테크놀로지’가 지난달 미국 Ghost Robotics Corp.(이하 ‘GRC’)에 사족 보행 로봇 Vision 60 핵심 주요부품 판매를 완료했다고 밝혔다. 이번 공급 물량은 1분기 판매한 물량 대비 5배 이상 규모이며, 3분기...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.